Treasurer of the State of North Carolina Has $3.71 Million Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Treasurer of the State of North Carolina reduced its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 7.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,169 shares of the company's stock after selling 943 shares during the period. Treasurer of the State of North Carolina's holdings in Medpace were worth $3,711,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Capital Fund Management S.A. grew its position in shares of Medpace by 73.9% in the fourth quarter. Capital Fund Management S.A. now owns 24,758 shares of the company's stock valued at $8,225,000 after purchasing an additional 10,520 shares during the last quarter. Bessemer Group Inc. increased its position in Medpace by 15.0% during the 4th quarter. Bessemer Group Inc. now owns 576,044 shares of the company's stock worth $191,379,000 after purchasing an additional 75,275 shares in the last quarter. Applied Finance Capital Management LLC acquired a new position in shares of Medpace during the 4th quarter valued at $246,000. Abacus FCF Advisors LLC raised its position in Medpace by 45.4% in the fourth quarter. Abacus FCF Advisors LLC now owns 9,528 shares of the company's stock valued at $3,165,000 after purchasing an additional 2,976 shares during the period. Finally, Renaissance Group LLC boosted its position in shares of Medpace by 11.3% in the fourth quarter. Renaissance Group LLC now owns 11,523 shares of the company's stock worth $3,828,000 after buying an additional 1,168 shares during the period. Hedge funds and other institutional investors own 77.98% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on MEDP. Leerink Partnrs raised Medpace to a "hold" rating in a research report on Monday, March 24th. Leerink Partners began coverage on Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 target price on the stock. Robert W. Baird lifted their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research note on Monday, January 27th. Mizuho cut their price target on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Finally, Truist Financial dropped their target price on shares of Medpace from $347.00 to $333.00 and set a "hold" rating for the company in a research report on Thursday, April 10th. Ten research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $357.50.

Medpace Stock Performance

Shares of Medpace stock traded down $0.22 during trading on Friday, hitting $296.28. 698,291 shares of the stock were exchanged, compared to its average volume of 325,831. Medpace Holdings, Inc. has a 12 month low of $272.00 and a 12 month high of $459.77. The stock has a market cap of $8.96 billion, a PE ratio of 23.46, a P/E/G ratio of 3.81 and a beta of 1.46. The stock's fifty day moving average is $318.52 and its 200 day moving average is $333.31.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.